These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 7267701)

  • 1. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
    Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
    Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
    Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
    Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
    Eichelbaum M; Bertilsson L; Säwe J
    Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
    Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
    Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolizers of debrisoquine, respectively.
    Tanaka E; Kobayashi S; Uchida E; Oguchi K; Yasuhara H
    Jpn J Pharmacol; 1989 Mar; 49(3):433-5. PubMed ID: 2747044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
    Bertilsson L; Eichelbaum M; Mellström B; Säwe J; Schulz HU; Sjöqvist F
    Life Sci; 1980 Nov; 27(18):1673-7. PubMed ID: 7442467
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential effects of enzyme induction on antipyrine metabolite formation.
    Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
    Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of changes in dietary fat on the clearance of antipyrine and 4-hydroxylation of debrisoquine.
    Mucklow JC; Caraher MT; Idle JR; Rawlins MD; Sloan T; Smith RL; Wood P
    Br J Clin Pharmacol; 1980 Mar; 9(3):283P. PubMed ID: 7362739
    [No Abstract]   [Full Text] [Related]  

  • 10. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.
    Sakai H; Kobayashi S; Hamada K; Iida S; Akita H; Tanaka E; Uchida E; Yasuhara H
    Br J Clin Pharmacol; 1991 Mar; 31(3):353-5. PubMed ID: 2054276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation.
    Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1981 Apr; 29(4):493-7. PubMed ID: 7471615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
    Davies DS; Kahn GC; Murray S; Brodie MJ; Boobis AR
    Br J Clin Pharmacol; 1981 Jan; 11(1):89-91. PubMed ID: 7213514
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
    Meier PJ; Mueller HK; Dick B; Meyer UA
    Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes.
    Lavrijsen KL; Van Houdt JM; Van Dyck DM; Hendrickx JJ; Woestenborghs RJ; Lauwers W; Meuldermans WE; Heykants JJ
    Anesthesiology; 1988 Oct; 69(4):535-40. PubMed ID: 3140691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
    Kallio J; Huupponen R; Pyykkö K
    Eur J Clin Pharmacol; 1990; 39(1):93-5. PubMed ID: 2276394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary bile acid and bile alcohol excretion does not reflect the genetic polymorphism of debrisoquine hydroxylation.
    Karlaganis G; Küpfer A; Preisig R
    Br J Clin Pharmacol; 1984 Apr; 17(4):470-3. PubMed ID: 6721994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.